Mylan N.V. June 15th Short Interest Update

Mylan N.V. (NASDAQ:MYL), According to the latest information the short interest in Mylan N.V. plummeted by 2.9% or 766,714 shares. The final shorts are 6.3% of the total floated shares. The positions dropped from 26,632,038 shares on May 31,2016 to 25,865,324 on June 15,2016. According to the per-day average trading of 4,842,686 shares, the days to cover are 5. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Mylan N.V. (NASDAQ:MYL): The stock opened at $43.68 on Friday but the bulls could not build on the opening and the stock topped out at $45.14 for the day. The stock traded down to $43.20 during the day, due to lack of any buying support eventually closed down at $43.56 with a loss of -5.63% for the day. The stock had closed at $46.16 on the previous day. The total traded volume was 9,367,084 shares.

The company shares have dropped -35.59% from its 1 Year high price. On Jul 6, 2015, the shares registered one year high at $73.90 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $43.25 and the 200 Day Moving Average price is recorded at $47.22.

Mylan N.V. (NASDAQ:MYL) has tumbled 3.22% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.16% in the last four weeks. The stocks have underperformed the S&P 500 by 1.62% during the past week but Mylan N.V. (NASDAQ:MYL) it has outperformed the index in 4 weeks by 4.22%.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *